Non-genetic risk factors and predicting efficacy for docetaxel-drug-induced liver injury among metastatic breast cancer patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 8, 2012, Pages 1348-1352

  Wang, Zheng ^a   Liang, Xu ^a   Yu, Jing ^a   Zheng, Xiaohui ^a   Zhu, Yulin ^a   Yan, Ying ^a   Dong, Ningning ^a   Di, Lijun ^a   Song, Guohong ^a   Zhou, Xinna ^a   Wang, Xiaoli ^a   Yang, Huabing ^a   Ren, Jun ^a   Lyerly, Herbert Kim ^b  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Docetaxel; Drug induced liver injury; Epidemiology

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL FEATURE; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; FEVER; HEPATITIS B; HUMAN; JAUNDICE; LIVER METASTASIS; LIVER PAIN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; NONALCOHOLIC FATTY LIVER; POSTMENOPAUSE; PREDICTIVE VALUE; PREMENOPAUSE; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TOXIC HEPATITIS; TREATMENT RESPONSE;

EID: 84864320108     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07131.x     Document Type: Article

References (25)

1. Ozer JS, Dieterle F, Troth S etal. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat. Biotechnol. 2010; 28: 486-94.
2. Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 2009; 10: 1467-87.
3. Lucena MI, Andrade RJ, Kaplowitz N etal. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009; 49: 2001-9.
4. Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010; 138: 2246-59.
5. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin. Liver Dis. 2009; 29: 337-47.
6. Chalasani N, Fontana RJ, Bonkovsky HL etal. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.
7. Lewis JH, Mortensen ME, Zweig S etal. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007; 46: 1453-63.
8. Russo MW, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology 2004; 126: 1477-80.
9. Lewis JH. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin. Drug Saf. 2002; 1: 159-72.
10. Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J. Hepatol. 2007; 47: 135-41.
11. Tarantino G, Conca P, Basile V etal. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol. Res. 2007; 37: 410-15.
12. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47: 2003-9.
13. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010; 51: 615-20.
14. Choti MA. Chemotherapy-associated hepatotoxicity: do we need to be concerned? Ann. Surg. Oncol. 2009; 16: 2391-4.
15. Ahn JH, Kim SB, Yun MR, Lee JS, Kang YK, Kim WK. Alternative therapy and abnormal liver function during adjuvant chemotherapy in breast cancer patients. J. Korean Med. Sci. 2004; 19: 397-400.
16. Trotti A, Colevas AD, Setser A etal. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 2003; 13: 176-81.
17. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J. Hepatol. 1990; 11: 272-6.
18. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment. Pharmacol. Ther. 2006; 24: 1187-95.
19. Andrade RJ, Lucena MI, Fernández MC etal. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.
20. Sgro C, Clinard F, Ouazir K etal. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-5.
21. Wu JC, Lee SD, Yeh PF etal. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98: 502-4.
22. Chen Y, Wei H, Sun R etal. Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells. Hepatology 2007; 46: 706-15.
23. Wilke RA, Lin DW, Roden DM etal. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 2007; 6: 904-16.
24. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin. Liver Dis. 2009; 29: 400-11.
25. Daly AK, Donaldson PT, Bhatnagar P etal. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 2009; 41: 816-19.